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Abstract
The American College of Cardiology Foundation, in col-
laboration with the Society for Cardiovascular Angiography
and Interventions and key specialty and subspecialty societies,
conducted a review of common clinical scenarios where diagnostic
catheterization is frequently considered.
The indications (clinical scenarios) were derived from
common applications or anticipated uses, as well as from
current clinical practice guidelines and results of studies
examining the implementation of noninvasive imaging ap-
propriate use criteria. The 166 indications in this document
were developed by a diverse writing group and scored by a
separate independent technical panel on a scale of 1 to 9, to
designate appropriate use (median 7 to 9), uncertain use
(median 4 to 6), and inappropriate use (median 1 to 3).
Diagnostic catheterization may include several different
procedure components. The indications developed focused
primarily on 2 aspects of diagnostic catheterization. Many
indications focused on the performance of coronary angiog-
raphy for the detection of coronary artery disease with other
procedure components (e.g., hemodynamic measurements,
ventriculography) at the discretion of the operator. The ma-
jority of the remaining indications focused on hemodynamic
measurements to evaluate valvular heart disease, pulmonary
hypertension, cardiomyopathy, and other conditions, with the
use of coronary angiography at the discretion of the operator.
Seventy-five indications were rated as appropriate, 49 were
rated as uncertain, and 42 were rated as inappropriate.
The appropriate use criteria for diagnostic catheterization
have the potential to impact physician decision making,
healthcare delivery, and reimbursement policy. Furthermore,
recognition of uncertain clinical scenarios facilitates identification
of areas that would benefit from future research.
Preface
In an effort to respond to the need for the rational use of
cardiovascular services, including imaging and invasive pro-
cedures in the delivery of high-quality care, the American
College of Cardiology Foundation (ACCF) in collaboration
with other professional organizations has undertaken a
process to determine the appropriate use of cardiovascular
procedures for selected patient indications.
Appropriate use criteria (AUC) publications reflect an
ongoing effort to critically and systematically create, review,and categorize clinical situations where diagnostic tests and
therapeutic procedures are utilized by physicians caring for
patients with cardiovascular disease. The process is based on
understanding the technical capabilities of the procedures
examined. The diversity of clinical disease present makes it
difficult to be comprehensive, but the indications presented
hopefully identify common scenarios encompassing the
majority of situations encountered in contemporary practice.
Given the breadth of information conveyed, the indications
do not directly correspond to the Ninth Revision of the
International Classification of Diseases system as these codes
do not include clinical information, such as symptom status.
The ACCF and the Society for Cardiovascular Angiog-
raphy and Interventions (SCAI) believe that careful blend-
ing of a broad range of clinical experiences and available
evidence-based information will help guide a more efficient
and equitable allocation of healthcare resources in cardiovas-
cular care and invasive catheterization. The ultimate objective
of the AUC is to improve patient care and health outcomes in
a cost-effective manner while recognizing that some ambiguity
and nuance is intrinsic to clinical decision making. Therefore,
the AUC should not be considered substitutes for sound
clinical judgment and practice experience. However, when the
clinical judgment and practice patterns routinely conflict with
AUC ratings, further evaluation of the specific clinical circum-
stances should be considered.
The AUC development process itself is also evolving.
Given the iterative nature of the process and incorporation
of new information about the role for diagnostic and
therapeutic interventions, readers are counseled that com-
parison of individual appropriate use ratings developed at
different times over the past several years may not reflect the
comparative utility of different modalities for a given indica-
tion, as the ratings may vary over time. Cardiac catheterization
plays a central role in the care of patients with cardiovascular
disease, and guidance around the rationale and evidence based
use of the procedure is the goal of the current document.
We are grateful to the technical panel and its moderator,
Pamela S. Douglas, MD, MACC, FAHA, FASE, a pro-
fessional group with a wide range of skills and insights, for
their thoughtful and thorough deliberation of the merits of
diagnostic catheterization for various indications. We would
also like to thank the 28 individuals who provided a careful
review of the draft of indications, the parent AUC Task
Force, and the ACCF staff, specifically Joseph M. Allen and
Lea Binder for their exceptionally skilled support in the
generation of this document.
Manesh R. Patel, MD, FACC
Co-Chair, Diagnostic Catheterization Writing Group
Steven R. Bailey, MD, FACC, FSCAI, FAHA
Co-Chair, Diagnostic Catheterization Writing Group
Michael J. Wolk, MD, MACC
Chair, Appropriate Use Criteria Task Force
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The ACCF, in collaboration with SCAI and several other
professional organizations, developed common clinical sce-
narios where diagnostic cardiac catheterization is frequently
considered. The indications, as presented in these clinical
scenarios, were derived from common presentations or
anticipated uses, as well as from current clinical practice
guidelines. The 166 indications in this document were
developed by a writing group with diverse clinical expertise
and scored by a separate independent technical panel on a
scale of 1 to 9, to designate appropriate use (median scores
7 to 9), uncertain use (median scores 4 to 6), and inappro-
priate use (median scores 1 to 3).
The AUC for diagnostic catheterization has the potential
to impact physician decision making, healthcare delivery,
and reimbursement policy. Furthermore, it is hoped that
recognition of uncertain clinical scenarios facilitates identi-
fication of areas that could benefit from future research.
This report addresses the appropriate use of diagnostic
catheterization. Improvements in cardiovascular imaging tech-
nology and an expanding array of noninvasive diagnostic tools
and therapeutic options for patients with cardiovascular disease
have led to many more choices than in the past. As the field
advances, the healthcare community needs to understand how
to best incorporate this technology into daily clinical care.
ACCF and SCAI are dedicated to this effort.
2. Methods
The indications included in this publication cover a variety
of cardiovascular signs and symptoms as well as clinical
judgments as to the likelihood of cardiovascular findings.
Within each main disease category, a standardized approach
was used to capture a significant number of clinical scenarios
without making the list of indications excessive. The term
“indication” is used interchangeably with “clinical scenario” in
the document for brevity and does not imply that imaging
should necessarily be done. Diagnostic catheterization may
include several different procedure components. The indica-
tions developed focused primarily on 2 aspects of diagnostic
catheterization. Many indications focused on the performance
of coronary angiography for the detection of coronary artery
disease (CAD), with other procedure components (e.g., he-
modynamic measurements, ventriculography) performed at the
discretion of the operator. The majority of the remaining
indications focused on hemodynamic measurements to evalu-
ate valvular heart disease, pulmonary hypertension, cardiomy-
opathy, and other conditions, with the addition of coronary
angiography at the discretion of the operator.
The spectrum of cardiovascular disease was addressed as
it would apply to the standard adult catheterization labora-
tory. The writing group did not consider invasive evalua-
tions of complex adult congenital heart disease in this
document, with the belief that such complex cases would bebest performed by individuals with considerable specialized
expertise and at institutions with sufficient patient volume.
Recommendations in this area are addressed in separate
subspecialty publications. Additionally, invasive procedures
such as endomyocardial biopsy, pericardiocentesis, or right
heart catheterization not performed in the catheterization
laboratory are not covered in this document.
The indications were constructed by a varied group of
experts in both invasive and noninvasive diagnostic cardiac
imaging. Subsequent modifications in the indications were
made based on discussions with the task force and feedback
from independent reviewers. Wherever possible, indications
were mapped to relevant clinical guidelines and key publi-
cations/references (see Online Appendix).
A detailed description of the methods used for rating the
selected clinical indications is found in a previous publica-
tion, “ACCF Proposed Method for Evaluating the Appro-
priateness of Cardiovascular Imaging” (1). Briefly, this process
combines evidence-based medicine and practice experience by
engaging a technical panel in a modified Delphi exercise. The
technical panel first rated the indications independently, after
which the results were summarized and the panel convened for
a face-to-face meeting to discuss each indication. At this
meeting, panel members were provided with their scores and a
blinded summary of their peers’ scores. After the meeting,
panel members once again independently rated each indication
to determine the final scores.
Although panel members were not provided explicit cost
information to help determine their ratings, they were asked to
implicitly consider costs as an additional factor in their evalu-
ation of appropriate use. In rating these criteria, the technical
panel was asked to assess whether the use of the test for each
indication is appropriate, uncertain, or inappropriate, and was
provided with the following definition of appropriate use:
An appropriate diagnostic cardiac catheterization (left
heart, right heart, ventriculography, and/or coronary an-
giography) is one in which the expected incremental infor-
mation combined with clinical judgment exceeds the negative
consequences by a sufficiently wide margin for a specific
indication that the procedure is generally considered accept-
able care and a reasonable approach for the indication.
Each member of the technical panel assigned a score to
each indication, and the scores of the technical panel were
tabulated for the final ratings and assigned an appropriate-
ness rating as follows:
Median Score 7 to 9
Appropriate test for specific indication (test is generally
acceptable and is a reasonable approach for the indication).
Median Score 4 to 6
Uncertain for specific indication (test may be generally
acceptable and may be a reasonable approach for the
indication). Uncertainty also implies that more research
1999JACC Vol. 59, No. 22, 2012 Patel et al.
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tion definitively.
Median Score 1 to 3
Inappropriate test for that indication (test is not generally
acceptable and is not a reasonable approach for the indication).
The division of these scores into 3 levels of appropriate-
ness should be viewed as a continuum. It is important to
emphasize that the category of “uncertain” is a distinct
category and must not be considered either “appropriate” or
“inappropriate” or lumped together with the other categories
when characterizing appropriateness ratings. A rating of
uncertain will exist if: 1) there is considerable diversity in the
ratings among individual members of the technical panel
indicating a wide range of opinions; 2) there is insufficient
clinical information provided in the clinical scenario for the
raters to reach a firm conclusion about appropriateness; or
3) there is a lack of specific information in the medical
literature to make a firm recommendation regarding appro-
priateness. The uncertain category designation should en-
courage investigators to perform definitive research when-
ever possible. A designation of “uncertain” does not imply
that the test should not be used in a specific clinical scenario.
Many other factors known by the clinician and difficult to
characterize within the structure of the AUC could affect a
decision to perform or not perform a procedure in a specific
patient. It is anticipated that the AUC reports will continue
to be revised as further data are generated and information
from the implementation of the criteria is accumulated. The
writing group recognizes that a large portion of routine
medical care would be rated as uncertain when held to the
standards of the AUC and therefore hope this rating is
correctly interpreted and can be placed in proper context.
To prevent bias in the scoring process, the technical panel
was deliberately comprised of a minority of specialists in
cardiac catheterization. Specialists, although offering impor-
tant clinical and technical insights, might have a natural
tendency to rate the indications within their specialty as
more appropriate than nonspecialists. In addition, care was
taken in providing objective, nonbiased information, includ-
ing guidelines and key references, to the technical panel.
The level of agreement among panelists as defined by
RAND (2) was analyzed based on the BIOMED rule for a
panel of 14 to 16 members. As such, agreement is defined as
an indication where 4 or fewer panelists’ ratings fell outside
the 3-point region containing the median score.
Disagreement was defined as where at least 5 panelists’
ratings fell in both the appropriate and the inappropriate
categories. Any indication having disagreement was catego-
rized as uncertain regardless of the final median score.
3. Assumptions
To limit inconsistencies in interpretation, specific assump-
tions were used by the writing group in drafting indicationsand by the technical panel when rating the clinical indica-
tions for the appropriate use of diagnostic catheterization.
1. The clinical scenarios were rated based on published
literature and clinical practice guidelines regarding the
risks and benefits of diagnostic catheterization, if avail-
able. In general, there are few randomized trials specif-
ically examining diagnostic catheterization as a proce-
dure. However, diagnostic catheterization was used
within the study design of many randomized trials in
which specific therapies were tested. Specific patient
groups not well represented in the literature are not
presented in the current clinical scenarios. However,
the writing group recognizes that decisions about diag-
nostic catheterization in such patients are frequently
required. Examples of such patients include those with
end-stage renal disease, advanced age, or malignancy.
2. All patients are attempting to achieve optimal care,
including guideline-based risk factor modification for
primary or secondary prevention in cardiovascular pa-
tients unless specifically noted (3–7).
3. Despite the best efforts of the clinician, all patients may
not achieve target goals for risk factor modification.
However, a plan of care to address risk factors is
assumed to be occurring in patients represented in the
indications. For patients with chronic stable angina, the
writing group recognizes that there is a wide variance in
the medical therapy for angina.
4. Operators performing diagnostic catheterization have
appropriate clinical training and experience and have
satisfactory outcomes as assessed by quality assurance
monitoring (8,9).
5. Diagnostic catheterization (left heart, right heart,
and/or coronary angiography) is performed in a manner
consistent with established standards of care (8,9).
6. All indications for diagnostic catheterization were con-
sidered with the following important assumptions:
a. All indications were first evaluated on the basis of
the available medical literature.
b. In many cases, studies published in the medical
literature provide minimal information about the
role of the test in clinical decision making.
c. Appropriate use criteria development requires a
risk/benefit trade-off as determined by individual
patient indications. Radiation exposure should be
considered in risk estimates.
d. No circumstances exist that would preclude cardiac
catheterization (e.g., severe coagulopathy, patient
refusal).
7. A complete clinical history and physical exam has been
completed by a qualified clinician such that the clinical
status of the patient can be assumed to be valid as stated
in the indication (e.g., asymptomatic patient is truly
asymptomatic for the condition in question and that sufficient
questioning of the patient has been undertaken).
(
e
e
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9. For each indication, the rating reflected whether diag-
nostic catheterization is reasonable for the patient and
not whether it is preferred over another modality.
10. The category of “uncertain” was used when insufficient
clinical data are available for a definitive categorization
or there is substantial disagreement regarding the ap-
propriateness of that indication. Those scenarios des-
ignated as uncertain reflect variations in clinical practice
patterns. The designation of “uncertain” should not
be used as grounds for denial of reimbursement.
11. All procedures presented are to be considered for
clinical indications and not part of a research protocol.
12. All prior noninvasive testing was adequately completed.
4. Definitions
Definitions of terms used throughout the indication set are
listed here. These definitions were provided to and dis-
cussed with the technical panel prior to rating of indications.
Stress Testing and Risk of Findings on Noninvasive
Testing: Stress testing is commonly used for both diagnosis
possible/presumed) and risk stratification of patients with
stablished CAD. Using criteria defined for traditional
xercise stress tests (10,11):
• Low-risk stress test findings: associated with a car-
diac mortality of 1% per year
• Intermediate-risk stress test findings: associated
with a 1% to 3% per year cardiac mortality
• High-risk stress test findings: associated with a 3%
per year cardiac mortality
Symptomatic/Ischemic Equivalent: Chest Pain Syn-
drome, Anginal Equivalent, or Ischemic Electrocardio-
gram (ECG) Abnormalities: Any constellation of clinical
findings that the physician believes is consistent with CAD
manifestations. Examples of such findings include, but are
not limited to, chest pain, chest tightness, chest burning,
shoulder pain, left arm pain, jaw pain, new ECG abnor-
malities, or other symptoms/findings suggestive of CAD.
Clinical presentations in the absence of chest pain (e.g.,
dyspnea with exertion or reduced/worsening effort toler-
ance) that are thought to be consistent with CAD may also
be considered to be an ischemic equivalent.
Clinical Classification of Chest Pain:
• Typical Angina (Definite): defined as 1) substernal
chest pain or discomfort that is 2) provoked by
exertion or emotional stress and 3) relieved by rest
and/or nitroglycerin (12).
• Atypical Angina (Probable): chest pain or discomfort
that lacks 1 of the characteristics of definite or typical
angina.• Nonanginal Chest Pain: chest pain or discomfort that
meets 1 or none of the typical angina characteristics.
Grading of Angina Pectoris by the Canadian Cardiovas-
cular Society Classification System (13):
Class I: ordinary physical activity does not cause angina, such
as walking, climbing stairs. Angina occurs with strenuous,
rapid, or prolonged exertion at work or recreation.
Class II: slight limitation of ordinary activity. Angina
occurs on walking more than 2 blocks on the level and
climbing more than 1 flight of ordinary stairs at a
normal pace and in normal condition.
Class III: marked limitations of ordinary physical activ-
ity. Angina occurs on walking 1 or 2 blocks on the
level and climbing 1 flight of stairs in normal condi-
tions and at a normal pace.
Class IV: inability to carry on any physical activity
without discomfort—anginal symptoms may be pres-
ent at rest.
Pretest Probability of Coronary Artery Disease: Symp-
tomatic (Ischemic Equivalent) Patients: Once the physician
determines that symptoms are present that may represent CAD,
the pretest probability of CAD should be assessed. There are a
number of risk algorithms (14,15) available that can be used to
calculate this probability. Clinicians should be familiar with those
algorithms that pertain to the populations they encounter
most often. In rating the appropriateness of cardiac cathe-
terization for specific indications, the following probabili-
ties, as calculated from any of the various available validated
algorithms, should be applied (10):
• Very low pretest probability: 5% pretest probability
of CAD
• Low pretest probability: between 5% and 10% pretest
probability of CAD
• Intermediate pretest probability: between 10% and
90% pretest probability of CAD
• High pretest probability:90% pretest probability of
CAD
The method recommended by the ACCF/AHA guide-
lines for chronic stable angina (10) is provided as one
example of a method used to calculate pretest probability
and is a modification of a previously published literature
review (16). Please refer to Table A and the clinical
classification of chest pain definition angina characteristics.
It is important to note that other historical factors or ECG
findings (e.g., prior infarction) can affect pretest probability,
although these factors are not accounted for in Table A.
Similarly, while not incorporated into the algorithm, other
CAD risk factors may also affect pretest likelihood of CAD.
Detailed nomograms are available that incorporate the
effects of a history of prior infarction, ECG Q waves and
ST- and T-wave changes, diabetes, smoking, and hyper-
cholesterolemia (17).
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current standard methods of global risk assessment such as
those presented in the National Heart, Lung, and Blood
Institute report on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult Treatment Panel
III [ATP III]) (19) or similar national guidelines.
Absolute risk is defined as the probability of developing
CAD over a given time period. The ATP III report
estimates the absolute risk for CAD over the next 10 years.
CAD risk refers to 10-year risk for any hard cardiac event
(e.g., myocardial infarction or CAD death). However,
acknowledging that global absolute risk scores may have not
been evaluated in certain populations (e.g., women, younger
men, minority populations), clinical judgment must be
applied in assigning categorical risk thresholds in such
subpopulations.
• Low global CAD risk
Defined by the age-specific risk level that is below
average. In general, low risk will correlate with a
10-year absolute CAD risk 10%. However, in
women and younger men, low risk may correlate with
10-year absolute CAD risk 6%.
• Intermediate global CAD risk
Defined by the age-specific risk level that is average.
In general, moderate risk will correlate with a 10-year
absolute CAD risk range of 10% to 20%. Among
women and younger men, an expanded intermediate
risk range of 6% to 20% may be appropriate.
• High global CAD risk
Defined by the age-specific risk level that is above
average. In general, high risk will correlate with a
10-year absolute CAD risk of 20%. CAD equiva-
lents (e.g., diabetes mellitus, peripheral arterial dis-
ease) can also define high risk.
uke Treadmill Score (20): The equation for calculating
he Duke treadmill score (DTS) is DTS  exercise time in
inutes  (5  ST-segment deviation)  (4  exercise
ngina), with 0  none, 1  nonlimiting, and 2 
Table A. Pretest Probability of CAD by Age, Gender, and Symp
Age (Yrs) Gender
Typical/Definite
Angina Pectoris
39 Men Intermediate
Women Intermediate
40–49 Men High
Women Intermediate
50–59 Men High
Women Intermediate
60 Men High
Women High
High: 90% pretest probability. Intermediate: between 10% and 90% pretest probability. Low: be
Exercise Testing Guidelines to reflect all age ranges (18).
CAD  coronary artery disease.xercise-limiting.The score typically ranges from 25 to 15. These
alues correspond to low-risk (with a score of 5),
oderate-risk (with scores ranging from 10 to 4), and
igh-risk (with a score of 11) categories.
CG—Uninterpretable: Refers to ECGs with resting
T-segment depression (0.10 mV), left bundle branch
lock (LBBB), pre-excitation (Wolff-Parkinson-White
yndrome), or paced rhythm.
djunct Invasive Diagnostic Testing:
• Fractional flow reserve (FFR)
An invasive diagnostic tool used to provide physi-
ological measurements as an adjunct to coronary
angiography for the determination of lesion sever-
ity and to assist in decisions about revasculariza-
tion. FFR is calculated using the ratio of the mean
arterial pressure distal to a stenosis to the mean
aortic pressure during maximal hyperemia. FFR
measurements 0.75 are associated with ischemia
on exercise testing and adjunct imaging (echo or
nuclear) with high sensitivity (88%), specificity
(100%), and overall accuracy (93%). FFR measure-
ments 0.80 are associated with negative ischemic
results with a predictive accuracy of 95%. Routine
measurement of FFR in patients with multivessel
coronary artery disease who are undergoing PCI
with drug-eluting stents with deferral of lesions
with FFR 0.80 has been shown to significantly
reduce the rate of the composite endpoint of death,
nonfatal myocardial infarction, and repeat revascu-
larization at 1 year (21).
• Intravascular ultrasound
An invasive diagnostic test performed as an adjunct
to diagnostic catheterization to provide an
ultrasound-based anatomic assessment that extends
beyond conventional angiography. This technique
is used to identify lesion and vessel characteristics
and obtain basic measurements for diagnostic and
*
typical/Probable
Angina Pectoris
Nonanginal
Chest Pain Asymptomatic
Intermediate Low Very low
Very low Very low Very low
Intermediate Intermediate Low
Low Very low Very low
Intermediate Intermediate Low
Intermediate Low Very low
Intermediate Intermediate Low
Intermediate Intermediate Low
5% and 10% pretest probability. Very low: 5% pretest probability. *Modified from the ACC/AHAtoms
A
tweeninterventional application (minimal and maximal
t. Mod
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area).
Evaluating Perioperative Risk for Noncardiac Surgery:
See Figure A, “Stepwise Approach to Perioperative
Cardiac Assessment,” from the ACCF/AHA 2009 peri-
operative guidelines (22). According to the algorithm,
once it is determined that the patient does not require
urgent surgery, the clinician should determine the
Figure A. Stepwise Approach to Perioperative Cardiac Assessm
Cardiac evaluation and care algorithm for noncardiac surgery based on active clinica
years of age. HR  heart rate; LOE  level of evidence; MET  metabolic equivalenpatient’s active cardiac conditions (see Table B) and/or
perioperative risk predictors (see Table C). If any active
cardiac conditions and/or major risk predictors are pres-
ent, Figure A suggests consideration of guideline-based
care that may include coronary angiography and postpon-
ing or canceling noncardiac surgery. Once perioperative
risk predictors are assessed, the surgical risk and the
patient’s functional status should be used to establish the
need for noninvasive testing.
itions, known cardiovascular disease, or cardiac risk factors for patients 50
ified from Fleisher et al. (22).ent
l cond
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ACS  acute coronary syndrome
AV  atrioventricular
ABG  coronary artery bypass grafting surgery
CAD  coronary artery disease
ECG  electrocardiogram
FFR  fractional flow reserve
LBBB  left bundle branch block
LV  left ventricular
6. Results of Ratings
The final ratings for diagnostic catheterization are listed by
indication in Tables 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 2.1, 2.2, 2.3, to
Table B. Active Cardiac Conditions for Which the Patient Shou
(Class I, Level of Evidence: B)
Condition
Unstable coronary syndromes Unstable or severe an
Recent MI‡
Decompensated HF (NYHA functional class IV;
worsening or new-onset HF)
Significant arrhythmias High-grade atrioventri
Mobitz II atrioventricu
Third-degree atriovent
Symptomatic ventricu
Supraventricular arrhy
(HR 100 beats/m
Symptomatic bradyca
Newly recognized vent
Severe valvular disease Severe aortic stenosis
Symptomatic mitral s
*According to Campeau (13); †may include “stable” angina in patients who are unusually seden
1 month (within 30 days).
CCS  Canadian Cardiovascular Society; HF  heart failure; HR  heart rate; MI  myocard
eprinted from Fleisher et al. (22).
Table C. Perioperative Clinical Risk Factors*
● History of ischemic heart disease
● History of compensated or prior heart failure
● History of cerebrovascular disease
● Diabetes mellitus (requiring insulin)
● Renal insufficiency (creatinine 2.0)
*As defined by the ACCF/AHA guidelines on perioperative cardiovascular evaluation and care for
noncardiac surgery (22). Note that these are not standard coronary artery disease risk factors.
ACCF  American College of Cardiology Foundation; AHA  American Heart Association..1. The final score reflects the median score of the 17echnical panel members and has been labeled according to
he 3 appropriate use categories of appropriate (median 7 to
), uncertain (median 4 to 6), and inappropriate (median 1
o 3). Tables 4, 5, and 6 present the same indications by the
ppropriate use categories.
7. Diagnostic Catheterization Appropriate
Use Criteria (by Indication)
A. CAD Assessment
1. Coronary Angiography With or Without Left
Heart Catheterization and Left Ventriculography
Coronary angiography is widely used to evaluate pa-
tients with known or suspected CAD. Depending on
the clinical circumstances and prior testing, coronary
angiography may be coupled with the measurement of
left ventricular (LV) pressures (left heart catheteriza-
tion) and/or the evaluation of LV systolic function and
wall motion (left ventriculography).
The indications developed in Section A relate to
appropriateness of coronary angiography. A deci-
sion about the performance of left heart catheter-
ization and left ventriculography is left to the
discretion of the operator and the patient’s primary
dergo Evaluation and Treatment Before Noncardiac Surgery
Examples
(CCS class III or IV)†
lock
ck
heart block
hythmias
s (including atrial fibrillation) with uncontrolled ventricular rate
est)
r tachycardia
n pressure gradient 40 mm Hg, aortic valve area 1.0 cm2, or symptomatic)
s (progressive dyspnea on exertion, extertional presyncope, or HF)
he American College of Cardiology National Database Library defines recent MI as 7 days but
ction; NYHA  New York Heart Association.ld Un
gina*
cular b
lar blo
ricular
lar arr
thmia
in at r
rdia
ricula
(mea
tenosi
tary; ‡tphysician.
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Indication Appropriate Use Score (1–9)
1. ● Cardiogenic shock due to suspected ACS A (9)
2. ● STEMI or suspected STEMI A (9)
Risk Score (e.g., TIMI, GRACE) Low Intermediate High
3. ● UA/NSTEMI A (7) A (8) A (9)
4. ● Suspected ACS with newly diagnosed LV wall motion abnormality or newly diagnosed resting myocardial
perfusion defect
A (7) A (8) A (9)A  appropriate; ACS  acute coronary syndrome; GRACE  Global Registry of Acute Coronary Events; LV  left ventricular; STEMI  ST-elevation myocardial infarction; TIMI  Thrombolysis In
yocardial Infarction; UA/NSTEMI  unstable angina non–ST-elevation myocardial infarction.Table 1.2. Suspected CAD: No Prior Noninvasive Stress Imaging (No Prior PCI, CABG, or Angiogram Showing >50%
Angiographic Stenosis)
Indication
Appropriate Use
Score (1–9)
Asymptomatic
5. ● Low global CAD risk I (1)
6. ● Intermediate global CAD risk I (3)
7. ● High global CAD risk U (4)
Symptomatic
8. ● Low pretest probability I (3)
9. ● Intermediate pretest probability U (6)
10. ● High pretest probability A (7)A  appropriate; CABG  coronary bypass grafting surgery; CAD  coronary artery disease; I  inappropriate; PCI  percutaneous coronary intervention; U  uncertain.Table 1.3. Suspected CAD: Prior Noninvasive Testing (No Prior PCI, CABG, or Angiogram Showing >50% Angiographic Stenosis)
Indication Appropriate Use Score (1–9)
ECG Stress Testing
Pretest Symptom Status
Asymptomatic Symptomatic
11. ● Low-risk findings (e.g., Duke treadmill score 5) I (1) U (4)
12. ● Intermediate-risk findings (e.g., Duke treadmill score 4 to 10) U (4) U (6)
13. ● High-risk findings (e.g., Duke treadmill score 11) A (7) A (8)
14. ● Other high-risk findings (ST-segment elevation, hypotension with exercise, ventricular tachycardia,
prolonged ST-segment depression)
A (7) A (9)
Stress Test With Imaging (SPECT MPI, Stress Echocardiography, Stress PET, Stress CMR)
Pretest Symptom Status
Asymptomatic Symptomatic
15. ● Low-risk findings (e.g., 5% ischemic myocardium on stress SPECT MPI or stress PET, no stress-induced
wall motion abnormalities on stress echo or stress CMR)
I (2) U (4)
16. ● Intermediate-risk findings (e.g., 5% to 10% ischemic myocardium on stress SPECT MPI or stress PET,
stress-induced wall motion abnormality in a single segment on stress echo or stress CMR)
U (4) A (7)
17. ● High-risk findings (e.g., 10% ischemic myocardium on stress SPECT MPI or stress PET, stress-induced
wall motion abnormality in 2 or more segments on stress echo or stress CMR)
A (7) A (9)
18. ● Other high-risk findings (e.g., TID, significant stress-induced LV dysfunction) A (7) A (8)
19. ● Discordant findings (e.g., low-risk prior imaging with ongoing symptoms consistent with ischemic
equivalent)
Not rated A (7)
20. ● Discordant findings (e.g., low-risk stress imaging with high-risk stress ECG response or stress-induced
typical angina)
U (5) A (7)
21. ● Equivocal/uninterpretable findings (e.g., perfusion defect vs. attenuation artifact, uninterpretable stress
imaging)
U (5) A (7)
22. ● Fixed perfusion defect on SPECT MPI or a persistent wall motion abnormality on stress echo consistent
with infarction without significant ischemia (5% ischemic myocardium)
U (4) U (6)
23. ● Baseline resting LV dysfunction (i.e., LVEF 40%) AND
● Evidence (e.g., PET, CMR, delayed thallium uptake, dobutamine echo) of myocardial viability in
dysfunctional segment
A (7) A (8)
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Indication Appropriate Use Score (1–9)
Echocardiography (TTE)
Pretest Symptom Status
Asymptomatic Symptomatic
24. ● Newly recognized LV systolic dysfunction (i.e., LVEF 40%) with an unknown etiology U (6) A (8)
25. ● Newly recognized LV systolic dysfunction (i.e., LVEF 41% to 49%) with an unknown etiology U (5) A (8)
26. ● New regional wall motion abnormality with an unknown etiology and normal LV systolic function U (5) A (7)
27. ● Suspected significant ischemic complication related to CAD (e.g., ischemic mitral regurgitation or VSD) A (9)
Coronary Calcium Score
Pretest Symptom Status
Asymptomatic Symptomatic
28. ● Agatston score 100 I (1) Not rated
29. ● Agatston score 100–400 I (2) Not rated
30. ● Agatston score 400–1,000 I (3) Not rated
31. ● Agatston score 1,000 I (3) Not rated
Coronary CTA
Pretest Symptom Status
Asymptomatic Symptomatic
32. ● Lesion 50% non-left main I (1) U (4)
33. ● Lesion 50% non-left main U (4) A (7)
34. ● Lesion 50% left main Not rated A (8)
35. ● Lesions 50% in more than 1 coronary territory U (5) A (7)
36. ● Lesion of unclear severity, possibly obstructive (non-left main) U (4) A (7)
37. ● Lesion of unclear severity, possibly obstructive (left main) A (7) A (8)
38. ● Lesion 50% with extensive partly calcified and non-calcified plaque I (3) U (5)
CMR
Pretest Symptom Status
Asymptomatic Symptomatic
39. ● Area of delayed gadolinium myocardial enhancement of unknown etiology I (3) Not rated
*Coronary calcium score only rated for asymptomatic patients as these patients are the population in which it is used.
A  appropriate; CABG  coronary bypass grafting surgery; CAD  coronary artery disease; CMR  cardiovascular magnetic resonance; CTA  computed tomography angiography; ECG electrocardiogram; I  inappropriate; LV  left ventricular; LVEF  left ventricular ejection fraction; PET  positron emission tomography; SPECT MPI  single-photon emission computed tomography
myocardial perfusion imaging; TID  transient ischemic dilation; TTE  transthoracic echocardiography; U  uncertain; VSD  ventricular septal defect.Table 1.4. Adjunctive Invasive Diagnostic Testing in Patients Undergoing Appropriate Diagnostic Coronary Angiography
Indication Appropriate Use Score (1–9)
Unexpected
Angiographic
Finding or No Prior
Noninvasive Testing
Prior
Testing 
No Ischemic
Findings
Prior Testing 
Concordant*
Ischemic Findings
FFR for Lesion Severity
40. ● Angiographically indeterminate severity left main stenosis (defined as 2 or more
orthogonal views contradictory whether stenosis 50%)
A (7) A (7) A (7)
41. ● Nonobstructive disease by angiography (non-left main) 50% I (3) I (2) U (5)
42. ● Angiographically intermediate disease (non-left main) 50% to 69% A (7) U (6) A (7)
43. ● Angiographically obstructive significant disease (non-left main) 70% stenosis A (7) A (7) I (3)
IVUS for Lesion Severity
44. ● Angiographically indeterminate left main stenosis (defined as 2 or more
orthogonal views contradictory whether stenosis 50%)
A (7) A (7) A (7)
45. ● Nonobstructive disease by angiography (non-left main) 50% I (3) I (3) U (6)
46. ● Angiographically intermediate disease (non-left main) 50% to 69% U (5) U (5) U (6)
47. ● Angiographically obstructive significant disease (non-left main) 70% stenosis U (4) U (5) I (3)
IVUS—Examination of Lesion or Artery Morphology
48. ● Coronary lesions or structures difficult to characterize angiographically (e.g., aneurysm, extent of calcification, stent
fracture, stent apposition, stent expansion, dissections) or for sizing of vessel before stent placement
A (8)
*Concordance refers to noninvasive imaging studies that demonstrate evidence of abnormal myocardial perfusion that is in the same distribution as a coronary artery stenosis, or degree of valvular
disease that is similar to clinical impression.
A  appropriate; FFR  fractional flow reserve; I  inappropriate; IVUS  intravascular ultrasound; U  uncertain.
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on Invasive Angiography)
Indication Appropriate Use Score (1–9)
Medically Managed Patients
Asymptomatic/Controlled
Symptoms OR Unchanged
Findings
Worsening or Limiting
Symptoms AND
Worsening Findings
49. ● Low-risk noninvasive findings I (2) U (6)
50. ● Intermediate-risk noninvasive findings U (4) A (7)
51. ● High-risk noninvasive findings A (7) A (9)
Post Revascularization (PCI or CABG)
52. ● Asymptomatic or stable symptoms I (1)
53. ● Low-risk noninvasive findings
● Worsening or limiting symptoms
U (6)
54. ● Intermediate-risk noninvasive findings
● Worsening or limiting symptoms
A (7)
55. ● High-risk noninvasive findings
● Worsening or limiting symptoms
A (8)
Post Revascularization (PCI)
56. ● Asymptomatic
● Prior unprotected left main PCI
U (5)A  appropriate; CABG  coronary bypass grafting surgery; CAD  coronary artery disease; I  inappropriate; MI  myocardial infarction; PCI  percutaneous coronary intervention; U  uncertain.Table 1.6. Arrhythmias
Indication Appropriate Use Score (1–9)
Etiology Unclear After Initial Evaluation
57. ● Resuscitated cardiac arrest with return of spontaneous circulation A (8)
58. ● VF or sustained VT with or without symptoms A (8)
59. ● Nonsustained VT (6 beats VT)
● Normal LV systolic function
U (5)
No Prior Noninvasive Assessment of Ischemia With Normal Systolic Function
CHD Risk Low Intermediate High
60. ● Syncope I (2) U (4) U (6)
61. ● New-onset atrial fibrillation or flutter I (2) I (3) U (5)
62. ● Heart block (e.g., second-degree type II or third-degree AV block) OR
● Symptomatic bradyarrhythmias
I (2) I (3) U (5)
63. ● Newly diagnosed LBBB U (4) U (5) U (6)A  appropriate; AV  atrioventricular; CHD  coronary heart disease; I  inappropriate; LBBB  left bundle branch block; LV  left ventricular; U  uncertain; VF  ventricular fibrillation;
T  ventricular tachycardia.Table 1.7. Preoperative Coronary Evaluation for Noncardiac Surgery in Stable Patients
Indication Appropriate Use Score (1–9)
64. ● Low-risk surgery I (2)
65. ● 4 METS functional capacity without symptoms I (2)
66 ● Prior to solid organ transplantation U (5)
<4 METS Functional Capacity, No Noninvasive Testing Performed, With or Without Clinical Risk Factors Present (Preoperative Clinical Risk Factors:
Ischemic Heart Disease, Heart Failure, Cerebrovascular Disease, Insulin-Requiring Diabetes Mellitus, Renal Insufficiency Cr >2.0)
Procedure Planned
Intermediate-Risk
Surgery
Vascular
Surgery
67. ● No risk factors I (2) I (3)
68. ● 1 to 2 risk factors I (3) U (4)
69. ● 3 risk factors U (4) U (6)Cr  creatinine; I  inappropriate; METS  metabolic equivalents; U  uncertain.
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Artery Disease
2. Right and Left Heart Catheterization or Right
Heart Catheterization Alone With or Without
Left Ventriculography and Coronary Angiography
Right and left heart catheterization (including the
measurement of cardiac output and intracardiac
oxygen saturations) is used to evaluate a variety of
conditions. The syndrome of heart failure may or
may not be present in these clinical scenarios.
Depending on the clinical circumstances and prior
testing, coronary angiography, left or right ven-
triculography, and additional angiography such as
supravalvular aortography may be coupled with
hemodynamic measurements. A decision about the
need for coronary angiography in addition to the
hemodynamic study should be at the discretion of
the operator and the patient’s primary physician.
2.1. Valvular Disease
Patients with valvular heart disease can be challenging
to evaluate, and these challenges are even greater in the
setting of multivalve involvement. Failure to intervene
with appropriate therapies at the correct time can result
in the permanent impairment of heart function and a
poor prognosis. The evaluation of valvular disease
should start with a careful history and physical exami-
nation and is then augmented by noninvasive imaging,
most frequently echocardiography. One of the chal-
lenges faced by clinicians occurs when the clinical
impression of valve lesion severity based on the history
and physical exam differs from that derived from an
imaging test. The presence of concordant or conflicting
impressions may affect the decision to perform an
Table 2.1. Valvular Disease
Indication
70. ● Preoperative assessment before valvular surgery
71. ● Pulmonary hypertension out of proportion to the severity of valv
72. ● Left ventricular dysfunction out of proportion to the severity of v
Chronic Native or Prinvasive evaluation and this is tested in the table below.
For patients in whom valve surgery is planned, the
indication for cardiac catheterization is covered in In-
dication 70.
Table 2.1 only considers isolated lesions of left-
sided valves and does not consider mixed disease of a
valve (e.g., aortic stenosis and regurgitation) or multi-
valve disease. Invasive evaluation may be necessary in
these settings but often requires the assessment of
several other variables such as LV function and should
be at the discretion of the clinician. Scenarios were not
developed for isolated or mixed disease of the tricuspid
or pulmonic valve because they are relatively uncommon
in adults and, when present, are often associated with
left-sided valve lesions.
2.2. Cardiomyopathies
A variety of conditions present with signs and/or
symptoms of heart failure. Right heart cathe-
terization alone or combined right and left heart
catheterization (including the measurement of car-
diac and pulmonary pressures, cardiac output, vas-
cular resistance, and intracardiac oxygen satura-
tions) is used to evaluate many of these conditions.
Depending on the clinical circumstances and prior
testing, coronary angiography, left or right ven-
triculography, and additional angiography may be
coupled with these hemodynamic measurements.
The indications developed below relate to appropri-
ateness of the right and left heart catheterization. A
decision about the performance of coronary angiog-
raphy should be at the discretion of the operator and
the patient’s primary physician.
Appropriate Use Score (1–9)
A (7)
isease A (8)
r disease A (8)
tic Valvular Diseaseular d
alvula
osthe
Asymptomatic Related to Valvular Disease
73. ● Mild or moderate mitral stenosis I (2)
74. ● Severe mitral stenosis U (6)
75. ● Mild or moderate mitral regurgitation I (2)
76. ● Severe mitral regurgitation U (5)
77. ● Mild or moderate aortic stenosis I (2)
78. ● Severe aortic stenosis U (4)
79. ● Mild or moderate aortic regurgitation I (2)
80. ● Severe aortic regurgitation U (5)
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In several clinical situations, the performance
of right heart catheterization (hemodynamics
Table 2.1. Continued
Indication
Chronic Native or Pr
Symptomatic Rela
Noninvasive Imaging for Valvular Disease
81. ● Mild or moderate mitral stenosis
82. ● Severe mitral stenosis
83. ● Mild or moderate mitral regurgitation
84. ● Severe mitral regurgitation
85. ● Mild or moderate aortic stenosis
86. ● Severe aortic stenosis
87. ● Equivocal aortic stenosis/low gradient aortic stenosis
● May include pharmacological challenge (e.g., dobutamine)
88. ● Mild or moderate aortic regurgitation
89. ● Severe aortic regurgitation
90. ● Acute moderate or severe mitral or aortic regurgitation
A  appropriate; I  inappropriate; U  uncertain.
Table 2.2. Pericardial Diseases
Indication
91. ● Suspected pericardial tamponade
92. ● Suspected or clinical uncertainty between constrictive vs. restric
A  appropriate.
Table 2.3. Cardiomyopathies
Indication
93. ● Known or suspected cardiomyopathy with or without heart failu
94. ● Re-evaluation of known cardiomyopathy
● Change in clinical status or cardiac exam or to guide therapy
95. ● Suspected arrhythmogenic right ventricular dysplasia
● Assessment of right ventricular morphology
A  appropriate; U  uncertain.
Table 3.1. Pulmonary Hypertension or Intracardiac Shunt Evalu
Indication
96. ● Known or suspected intracardiac shunt with indeterminate shun
Evaluation of Pu
97. ● Suspected pulmonary artery hypertension
● Equivocal or borderline elevated estimated right ventricular sys
98. ● Suspected pulmonary hypertension
● Elevated estimated right ventricular systolic pressure on resting
99. ● Resting pulmonary hypertension
● Determine response to pulmonary vasodilators given in cath lab
100. ● Resting pulmonary hypertension
● Determine response after initiation of drug therapy
101. ● Post heart transplant patient
● With or without the performance of endomyocardial biopsy
102. ● Indeterminate intravascular volume status
● Etiology unclear after initial evaluationA  appropriate.and cardiac output) alone is used. This can
be performed in the cardiac catheterization
laboratory.
Appropriate Use Score (1–9)
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Table 4. Appropriate Indications (Median Score 7–9)
Indication
Appropriate Use
Score (1–9)
Suspected Acute Coronary Syndrome
1. ● Cardiogenic shock due to suspected ACS A (9)
2. ● STEMI or suspected STEMI A (9)
3. ● UA/NSTEMI
● Low-risk score (e.g., TIMI, GRACE)
A (7)
3. ● UA/NSTEMI
● Intermediate-risk score (e.g., TIMI, GRACE)
A (8)
3. ● UA/NSTEMI
● High-risk score (e.g., TIMI, GRACE)
A (9)
4. ● Suspected ACS with newly diagnosed LV wall motion abnormality or newly diagnosed resting myocardial perfusion
defect
● Low-risk score (e.g., TIMI, GRACE)
A (7)
4. ● Suspected ACS with newly diagnosed LV wall motion abnormality or newly diagnosed resting myocardial perfusion
defect
● Intermediate risk score (e.g., TIMI, GRACE)
A (8)
4. ● Suspected ACS with newly diagnosed LV wall motion abnormality or newly diagnosed resting myocardial perfusion
defect
● High-risk score (e.g., TIMI, GRACE)
A (9)
Suspected CAD: No Prior Noninvasive Stress Imaging (No Prior PCI, CABG, or Angiogram Showing >50% Angiographic Stenosis)
10. ● High pretest probability
● Symptomatic
A (7)
Suspected CAD: Prior Noninvasive Testing (No Prior PCI, CABG, or Angiogram Showing >50% Angiographic Stenosis)
ECG Stress Testing
13. ● High-risk findings (e.g., Duke treadmill score 11)
● Asymptomatic
A (7)
13. ● High-risk findings (e.g., Duke treadmill score 11)
● Symptomatic
A (8)
14. ● Other high-risk finding (ST-segment elevation, hypotension with exercise, ventricular tachycardia, prolonged ST-
segment depression)
● Asymptomatic
A (7)
14. ● Other high-risk finding (ST-segment elevation, hypotension with exercise, ventricular tachycardia, prolonged ST-
segment depression)
● Symptomatic
A (9)
Stress Test With Imaging (SPECT MPI, Stress Echocardiography, Stress PET, Stress CMR)
16. ● Intermediate-risk findings (e.g., 5% to 10% ischemic myocardium on stress SPECT MPI or stress PET, stress-induced
wall motion abnormality in a single segment on stress echo or stress CMR)
● Symptomatic
A (7)
17. ● High-risk findings (e.g., 10% ischemic myocardium on stress SPECT MPI or stress PET, stress-induced wall motion
abnormality in 2 or more segments on stress echo or stress CMR)
● Asymptomatic
A (7)
17. ● High-risk findings (e.g., 10% ischemic myocardium on stress SPECT MPI or stress PET, stress-induced wall motion
abnormality in 2 or more segments on stress echo or stress CMR)
● Symptomatic
A (9)
18. ● Other high-risk finding (e.g., TID, significant stress-induced LV dysfunction)
● Asymptomatic
A (7)
18. ● Other high-risk finding (e.g., TID, significant stress-induced LV dysfunction)
● Symptomatic
A (8)
19. ● Discordant findings (e.g., low-risk prior imaging with ongoing symptoms consistent with ischemic equivalent)
● Symptomatic
A (7)
20. ● Discordant findings (e.g., low-risk stress imaging with high-risk stress ECG response or stress-induced typical angina)
● Symptomatic
A (7)
21. ● Equivocal/uninterpretable findings (e.g., perfusion defect vs. attenuation artifact, uninterpretable stress imaging)
● Symptomatic
A (7)
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Indication
Appropriate Use
Score (1–9)
23. ● Baseline resting LV dysfunction (i.e., LVEF 40%) AND
● Evidence (e.g., PET, CMR, delayed thallium uptake, dobutamine echo) of myocardial viability in dysfunctional
segment
● Asymptomatic
A (7)
23. ● Baseline resting LV dysfunction (i.e., LVEF 40%) AND
● Evidence (e.g., PET, CMR, delayed thallium uptake, dobutamine echo) of myocardial viability in dysfunctional
segment
● Symptomatic
A (8)
Echocardiography (TTE)
24. ● Newly recognized LV systolic dysfunction (i.e., LVEF 40%) with an unknown etiology
● Symptomatic
A (8)
25. ● Newly recognized LV systolic dysfunction (i.e., LVEF 41% to 49%) with an unknown etiology
● Symptomatic
A (8)
26. ● New regional wall motion abnormality with an unknown etiology and normal LV systolic function
● Symptomatic
A (7)
27. ● Suspected significant ischemic complication related to CAD (e.g., ischemic mitral regurgitation or VSD) A (9)
Coronary CTA
33. ● Lesion 50% non-left main
● Symptomatic
A (7)
34. ● Lesion 50% left main
● Symptomatic
A (8)
35. ● Lesions 50% in more than 1 coronary territory
● Symptomatic
A (7)
36. ● Lesion of unclear severity, possibly obstructive (non-left main)
● Symptomatic
A (7)
37. ● Lesion of unclear severity, possibly obstructive (left main)
● Asymptomatic
A (7)
37. ● Lesion of unclear severity, possibly obstructive (left main)
● Symptomatic
A (8)
Adjunctive Invasive Diagnostic Testing in Patients Undergoing Appropriate Diagnostic Coronary Angiography
FFR for Lesion Severity
40. ● Angiographically indeterminate severity left main stenosis (defined as 2 or more orthogonal views contradictory
whether stenosis 50%)
● Unexpected angiographic finding or no prior noninvasive testing
A (7)
40. ● Angiographically indeterminate severity left main stenosis (defined as 2 or more orthogonal views contradictory
whether stenosis 50%)
● Prior testing  no ischemic findings
A (7)
40. ● Angiographically indeterminate severity left main stenosis (defined as 2 or more orthogonal views contradictory
whether stenosis 50%)
● Prior testing  concordant ischemic findings
A (7)
42. ● Angiographically intermediate disease (non-left main) 50% to 69%
● Unexpected angiographic finding or no prior noninvasive testing
A (7)
42. ● Angiographically intermediate disease (non-left main) 50% to 69%
● Prior testing  concordant ischemic findings
A (7)
43. ● Angiographically obstructive significant disease (non-left main) 70% stenosis
● Unexpected angiographic finding or no prior noninvasive testing
A (7)
43. ● Angiographically obstructive significant disease (non-left main) 70% stenosis
● Prior testing  no ischemic findings
A (7)
IVUS for Lesion Severity
44. ● Angiographically indeterminate severity left main stenosis (defined as 2 or more orthogonal views contradictory
whether stenosis 50%)
● Unexpected angiographic finding or no prior noninvasive testing
A (7)
44. ● Angiographically indeterminate severity left main stenosis (defined as 2 or more orthogonal views contradictory
whether stenosis 50%)
● Prior testing  no ischemic findings
A (7)
44. ● Angiographically indeterminate severity left main stenosis (defined as 2 or more orthogonal views contradictory
whether stenosis 50%)
● Prior testing  concordant ischemic findings
A (7)
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Indication
Appropriate Use
Score (1–9)
IVUS—Examination of Lesion or Artery Morphology
48. ● Coronary lesions or structures difficult to characterize angiographically (e.g., aneurysm, extent of calcification, stent
fracture, stent apposition, stent expansion, dissections) or for sizing of vessel before stent placement
A (8)
Patients With Known Obstructive CAD (e.g., Prior MI, Prior PCI, Prior CABG, or Obstructive Disease on Invasive Angiography)
Medically Managed Patients
50. ● Intermediate-risk noninvasive findings
● Worsening or limiting symptoms and worsening findings
A (7)
51. ● High-risk noninvasive findings
● Asymptomatic/controlled symptoms or unchanged findings
A (7)
51. ● High-risk noninvasive findings
● Worsening or limiting symptoms and worsening findings
A (9)
Post Revascularization (PCI or CABG)
54. ● Intermediate-risk noninvasive findings
● Worsening or limiting symptoms
A (7)
55. ● High-risk noninvasive findings
● Worsening or limiting symptoms
A (8)
Arrhythmias
Etiology Unclear After Initial Evaluation
57. ● Resuscitated cardiac arrest with return of spontaneous circulation A (8)
58. ● VF or sustained VT with or without symptoms A (8)
Valvular Disease
70. ● Preoperative assessment before valvular surgery A (7)
71. ● Pulmonary hypertension out of proportion to the severity of valvular disease A (8)
72. ● Left ventricular dysfunction out of proportion to the severity of valvular disease A (8)
Chronic Native or Prosthetic Valvular Disease
Symptomatic Related to Valvular Disease
81. ● Mild or moderate mitral stenosis
● Noninvasive imaging for valvular disease conflicting with clinical impression of severity
A (7)
82. ● Severe mitral stenosis
● Noninvasive imaging for valvular disease conflicting with clinical impression of severity
A (7)
83. ● Mild or moderate mitral regurgitation
● Noninvasive imaging for valvular disease conflicting with clinical impression of severity
A (7)
84. ● Severe mitral regurgitation
● Noninvasive imaging for valvular disease conflicting with clinical impression of severity
A (7)
85. ● Mild or moderate aortic stenosis
● Noninvasive imaging for valvular disease conflicting with clinical impression of severity
A (7)
86. ● Severe aortic stenosis
● Noninvasive imaging for valvular disease conflicting with clinical impression of severity
A (8)
87. ● Equivocal aortic stenosis/low gradient aortic stenosis
● May include pharmacological challenge (e.g., dobutamine)
● Noninvasive imaging for valvular disease conflicting with clinical impression of severity
A (8)
88. ● Mild or moderate aortic regurgitation
● Noninvasive imaging for valvular disease conflicting with clinical impression of severity
A (7)
89. ● Severe aortic regurgitation
● Noninvasive imaging for valvular disease conflicting with clinical impression of severity
A (8)
90. ● Acute moderate or severe mitral or aortic regurgitation
● Noninvasive imaging for valvular disease conflicting with clinical impression of severity
A (8)
Pericardial Diseases
91. ● Suspected pericardial tamponade A (8)
92. ● Suspected or clinical uncertainty between constrictive vs. restrictive physiology A (8)
Cardiomyopathies
93. ● Known or suspected cardiomyopathy with or without heart failure A (7)
94. ● Re-evaluation of known cardiomyopathy
● Change in clinical status or cardiac exam or to guide therapy
A (7)
Pulmonary Hypertension or Intracardiac Shunt Evaluation
96. ● Known or suspected intracardiac shunt with indeterminate shunt anatomy or shunt fraction A (8)
e
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Indication
Appropriate Use
Score (1–9)
Evaluation of Pulmonary Hypertension
97. ● Suspected pulmonary artery hypertension
● Equivocal or borderline elevated estimated right ventricular systolic pressure on resting echo study
A (7)
98. ● Suspected pulmonary hypertension
● Elevated estimated right ventricular systolic pressure on resting echo study
A (7)
99. ● Resting pulmonary hypertension
● Determine response to pulmonary vasodilators given in cath lab
A (8)
100. ● Resting pulmonary hypertension
● Determine response after initiation of drug therapy
A (7)
101. ● Post heart transplant patient
● With or without the performance of endomyocardial biopsy
A (7)
102. ● Indeterminate intravascular volume status
● Etiology unclear after initial evaluation
A (7)
A  appropriate; ACS  acute coronary syndrome; CABG  coronary bypass grafting surgery; CAD  coronary artery disease; CMR  cardiovascular magnetic resonance; CTA  computed tomography
angiography; ECG  electrocardiogram; FFR  fractional flow reserve; GRACE  Global Registry of Acute Coronary Events; IVUS  intravascular ultrasound; LV  left ventricular; LVEF  left ventricular
jection fraction; MI  myocardial infarction; PET  positron emission tomography; PCI  percutaneous coronary intervention; SPECT MPI  single-photon emission computed tomography myocardial
erfusion imaging; STEMI  ST-elevation myocardial infarction; TID  transient ischemic dilation; TIMI  Thrombolysis In Myocardial Infarction; TTE  transthoracic echocardiography; UA/NSTEMI 
nstable angina/non–ST-elevation myocardial infarction; VF  ventricular fibrillation; VSD  ventricular septal defect; VT  ventricular tachycardia.Table 5. Uncertain Indications (Median Score 4–6)
Indication
Appropriate Use
Score (1–9)
Suspected CAD: No Prior Noninvasive Stress Imaging (No Prior PCI, CABG, or Angiogram Showing >50% Angiographic Stenosis)
7. ● High global CAD risk
● Asymptomatic
U (4)
9. ● Intermediate pretest probability
● Symptomatic
U (6)
Suspected CAD: Prior Noninvasive Testing (No Prior PCI, CABG, or Angiogram Showing >50% Angiographic Stenosis)
ECG Stress Testing
11. ● Low-risk findings (e.g., Duke treadmill score 5)
● Symptomatic
U (4)
12. ● Intermediate-risk findings (e.g., Duke treadmill score 4 to 10)
● Asymptomatic
U (4)
12. ● Intermediate-risk findings (e.g., Duke treadmill score 4 to 10)
● Symptomatic
U (6)
Stress Test With Imaging (SPECT MPI, Stress Echocardiography, Stress PET, Stress CMR)
15. ● Low-risk findings (e.g., 5% ischemic myocardium on stress SPECT MPI or stress PET, no stress-induced wall
motion abnormalities on stress echo or stress CMR)
● Symptomatic
U (4)
16. ● Intermediate-risk findings (e.g., 5% to 10% ischemic myocardium on stress SPECT MPI or stress PET, stress-induced
wall motion abnormality in a single segment on stress echo or stress CMR)
● Asymptomatic
U (4)
20. ● Discordant findings (e.g., low-risk stress imaging with high-risk stress ECG response or stress-induced typical angina)
● Asymptomatic
U (5)
21. ● Equivocal/uninterpretable findings (e.g., perfusion defect vs. attenuation artifact, uninterpretable stress imaging)
● Asymptomatic
U (5)
22. ● Fixed perfusion defect on SPECT MPI or a persistent wall motion abnormality on stress echo consistent with
infarction without significant ischemia (5% ischemic myocardium)
● Asymptomatic
U (4)
22. ● Fixed perfusion defect on SPECT MPI or a persistent wall motion abnormality on stress echo consistent with
infarction without significant ischemia (5% ischemic myocardium)
● Symptomatic
U (6)
Echocardiography (TTE)
24. ● Newly recognized LV systolic dysfunction (i.e., LVEF 40%) with an unknown etiology
● Asymptomatic
U (6)
25. ● Newly recognized LV systolic dysfunction (i.e., LVEF 41% to 49%) with an unknown etiology
● Asymptomatic
U (5)
26. ● New regional wall motion abnormality with an unknown etiology and normal LV systolic function
● Asymptomatic
U (5)
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Indication
Appropriate Use
Score (1–9)
Coronary CTA
32. ● Lesion 50% non-left main
● Symptomatic
U (4)
33. ● Lesion 50% non-left main
● Asymptomatic
U (4)
35. ● Lesions 50% in more than 1 coronary territory
● Asymptomatic
U (5)
36. ● Lesion of unclear severity, possibly obstructive (non-left main)
● Asymptomatic
U (4)
38. ● Lesion 50% with extensive partly calcified and noncalcified plaque
● Symptomatic
U (5)
Adjunctive Invasive Diagnostic Testing in Patients Undergoing Appropriate Diagnostic Coronary Angiography
FFR for Lesion Severity
41. ● Nonobstructive disease by angiography (non-left main) 50%
● Prior testing  concordant ischemic findings
U (5)
42. ● Angiographically intermediate disease (non-left main) 50% to 69%
● Prior testing  no ischemic findings
U (6)
IVUS for Lesion Severity
45. ● Non-obstructive disease by angiography (non-left main) 50%
● Prior testing  concordant ischemic findings
U (6)
46. ● Angiographically intermediate disease (non-left main) 50% to 69%
● Unexpected angiographic finding or no prior noninvasive testing
U (5)
46. ● Angiographically intermediate disease (non-left main) 50% to 69%
● Prior testing  no ischemic findings
U (5)
46. ● Angiographically intermediate disease (non-left main) 50% to 69%
● Prior testing  concordant ischemic findings
U (6)
47. ● Angiographically obstructive significant disease (non-left main) 70% stenosis
● Unexpected angiographic finding or no prior noninvasive testing
U (4)
47. ● Angiographically obstructive significant disease (non-left main) 70% stenosis
● Prior testing  no ischemic findings
U (5)
Patients With Known Obstructive CAD (e.g., Prior MI, Prior PCI, Prior CABG, or Obstructive Disease on Invasive Angiography)
Medically Managed Patients
49. ● Low-risk noninvasive findings
● Worsening or limiting symptoms and worsening findings
U (6)
50. ● Intermediate-risk noninvasive findings
● Asymptomatic/controlled symptoms or unchanged findings
U (4)
Post Revascularization (PCI or CABG)
53. ● Low-risk noninvasive findings
● Worsening or limiting symptoms
U (6)
Post Revascularization (PCI)
56. ● Asymptomatic
● Prior unprotected left main PCI
U (5)
Arrhythmias
Etiology Unclear After Initial Evaluation
59. ● Nonsustained VT (6 beats VT)
● Normal LV systolic function
U (5)
No Prior Noninvasive Assessment of Ischemia With Normal Systolic Function
60. ● Syncope
● Intermediate CHD risk
U (4)
60. ● Syncope
● High CHD risk
U (6)
61. ● New-onset atrial fibrillation or flutter
● High CHD risk
U (5)
62. ● Heart block (e.g., second-degree type II or third-degree AV block) OR
● Symptomatic bradyarrhythmias
● High CHD risk
U (5)
63. ● Newly diagnosed LBBB
● Low CHD risk
U (4)
c
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Indication
Appropriate Use
Score (1–9)
63. ● Newly diagnosed LBBB
● Intermediate CHD risk
U (5)
63. ● Newly diagnosed LBBB
● High CHD risk
U (6)
Preoperative Coronary Evaluation for Noncardiac Surgery in Stable Patients
66. ● Prior to solid organ transplantation U (5)
<4 METS Functional Capacity, No Noninvasive Testing Performed, With or Without Clinical Risk Factors Present (Preoperative Clinical Risk Factors:
Ischemic Heart Disease, Heart Failure, Cerebrovascular Disease, Insulin-Requiring Diabetes Mellitus, Renal Insufficiency Cr >2.0)
68. ● 1 to 2 risk factors
● Vascular surgery
U (4)
69. ● 3 risk factors
● Intermediate-risk surgery
U (4)
69. ● 3 risk factors
● Vascular surgery
U (6)
Valvular Disease
Chronic Native or Prosthetic Valvular Disease
Asymptomatic Related to Valvular Disease
74. ● Severe mitral stenosis U (6)
76. ● Severe mitral regurgitation U (5)
78. ● Severe aortic stenosis U (4)
80. ● Severe aortic regurgitation U (5)
Chronic Native or Prosthetic Valvular Disease
Symptomatic Related to Valvular Disease
90. ● Acute moderate or severe mitral or aortic regurgitation
● Noninvasive imaging for valvular disease concordant with clinical impression of severity
U (4)
Cardiomyopathies
95. ● Suspected arrhythmogenic right ventricular dysplasia
● Assessment of right ventricular morphology
U (5)
AV  atrioventricular; CABG  coronary bypass grafting surgery; CAD  coronary artery disease; CHD  coronary heart disease; CMR  cardiovascular magnetic resonance; Cr  creatinine; CTA 
omputed tomography angiography; ECG  electrocardiogram; FFR  fractional flow reserve; IVUS  intravascular ultrasound; LBBB  left bundle branch block; LV  left ventricular; LVEF  left
entricular ejection fraction; METS  metabolic equivalents; MI  myocardial infarction; PCI  percutaneous coronary intervention; PET  positron emission tomography; SPECT MPI  single-photon
mission computed tomography myocardial perfusion imaging; TTE  transthoracic echocardiography; U  uncertain; VT  ventricular tachycardia.Table 6. Inappropriate Indications (Median Score 1–3)
Indication
Appropriate Use
Score (1–9)
Suspected CAD: No Prior Noninvasive Stress Imaging (No Prior PCI, CABG, or Angiogram Showing >50% Angiographic Stenosis)
5. ● Low global CAD risk
● Asymptomatic
I (1)
6. ● Intermediate global CAD risk
● Asymptomatic
I (3)
8. ● Low pretest probability
● Symptomatic
I (3)
Suspected CAD: Prior Noninvasive Testing (No Prior PCI, CABG, or Angiogram Showing >50% Angiographic Stenosis)
ECG Stress Testing
11. ● Low-risk findings (e.g., Duke treadmill score 5)
● Asymptomatic
I (1)
Stress Test With Imaging (SPECT MPI, Stress Echocardiography, Stress PET, Stress CMR)
15. ● Low-risk findings (e.g., 5% ischemic myocardium on stress SPECT MPI or stress PET, no stress-induced wall motion
abnormalities on stress echo or stress CMR)
● Asymptomatic
I (2)
Coronary Calcium Score
28. ● Agatston score 100
● Asymptomatic
I (1)
29. ● Agatston score 100 to 400
● Asymptomatic
I (2)
30. ● Agatston score 400–1,000
● Asymptomatic
I (3)
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Indication
Appropriate Use
Score (1–9)
31. ● Agatston score 1,000
● Asymptomatic
I (3)
Coronary CTA
32. ● Lesion 50% non-left main
● Asymptomatic
I (1)
38. ● Lesion 50% with extensive partly calcified and noncalcified plaque
● Asymptomatic
I (3)
CMR
39. ● Area of delayed gadolinium myocardial enhancement of unknown etiology
● Asymptomatic
I (3)
Adjunctive Invasive Diagnostic Testing in Patients Undergoing Appropriate Diagnostic Coronary Angiography
FFR for Lesion Severity
41. ● Nonobstructive disease by angiography (non-left main) 50%
● Unexpected angiographic finding or no prior noninvasive testing
I (3)
41. ● Nonobstructive disease by angiography (non-left main) 50%
● Prior testing  no ischemic findings
I (2)
43. ● Angiographically obstructive significant disease (non-left main) 70% stenosis
● Prior testing  concordant ischemic findings
I (3)
IVUS for Lesion Severity
45. ● Nonobstructive disease by angiography (non-left main) 50%
● Unexpected angiographic finding or no prior noninvasive testing
I (3)
45. ● Nonobstructive disease by angiography (non-left main) 50%
● Prior testing  no ischemic findings
I (3)
47. ● Angiographically obstructive significant disease (non-left main) 70% stenosis
● Prior testing  concordant ischemic findings
I (3)
Patients With Known Obstructive CAD (e.g., Prior MI, Prior PCI, Prior CABG, or Obstructive Disease on Invasive Angiography)
Medically Managed Patients
49. ● Low-risk noninvasive findings
● Asymptomatic/controlled symptoms or unchanged findings
I (2)
Post Revascularization (PCI or CABG)
52. ● Asymptomatic or stable symptoms I (1)
Arrhythmias
No Prior Noninvasive Assessment of Ischemia With Normal Systolic Function
60. ● Syncope
● Low CHD risk
I (2)
61. ● New-onset atrial fibrillation or flutter
● Low CHD risk
I (2)
61. ● New-onset atrial fibrillation or flutter
● Intermediate CHD risk
I (3)
62. ● Heart block (e.g., second-degree type II or third-degree AV block) OR
● Symptomatic bradyarrhythmias
● Low CHD risk
I (2)
62. ● Heart block (e.g., second-degree type II or third-degree AV block) OR
● Symptomatic bradyarrhythmias
● Intermediate CHD risk
I (3)
Preoperative Coronary Evaluation for Noncardiac Surgery in Stable Patients
64. ● Low-risk surgery I (2)
65. ● 4 METS functional capacity without symptoms I (2)
<4 METS Functional Capacity, No Noninvasive Testing Performed, With or Without Clinical Risk Factors Present (Preoperative Clinical Risk Factors:
Ischemic Heart Disease, Heart Failure, Cerebrovascular Disease, Insulin-Requiring Diabetes Mellitus, Renal Insufficiency Cr >2.0)
67. ● No risk factors
● Intermediate-risk surgery
I (2)
67. ● No risk factors
● Vascular surgery
I (3)
68. ● 1 to 2 risk factors
● Intermediate-risk surgery
I (3)
c  inappropriate; IVUS  intravascular ultrasound; METS  metabolic equivalents; MI  myocardial
ECT MPI  single-photon emission computed tomography myocardial perfusion imaging.
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Figure 1. Suspected CAD: No Prior Noninvasive Stress
Imaging
A  appropriate; CAD  coronary artery disease; I  inappropriate; U  uncertain.
Table 6. Continued
Indication
Valvul
Chronic Native or Pr
Asymptomatic Rela
73. ● Mild or moderate mitral stenosis
75. ● Mild or moderate mitral regurgitation
77. ● Mild or moderate aortic stenosis
79. ● Mild or moderate aortic regurgitation
Chronic Native or Pr
Symptomatic Rela
81. ● Mild or moderate mitral stenosis
● Noninvasive imaging for valvular disease concordant with clin
82. ● Severe mitral stenosis
● Noninvasive imaging for valvular disease concordant with clin
83. ● Mild or moderate mitral regurgitation
● Noninvasive imaging for valvular disease concordant with clin
84. ● Severe mitral regurgitation
● Noninvasive imaging for valvular disease concordant with clin
85. ● Mild or moderate aortic stenosis
● Noninvasive imaging for valvular disease concordant with clin
86. ● Severe aortic stenosis
● Noninvasive imaging for valvular disease concordant with clin
88. ● Mild or moderate aortic regurgitation
● Noninvasive imaging for valvular disease concordant with clin
89. ● Severe aortic regurgitation
● Noninvasive imaging for valvular disease concordant with clin
AV  atrioventricular; CABG  coronary bypass grafting surgery; CAD  coronary artery disease
omputed tomography angiography; ECG  electrocardiogram; FFR  fractional flow reserve; I
infarction; PCI  percutaneous coronary intervention; PET  positron emission tomography; SPAppropriate Use
Score (1–9)
ar Disease
osthetic Valvular Disease
ted to Valvular Disease
I (2)
I (2)
I (2)
I (2)
osthetic Valvular Disease
ted to Valvular Disease
ical impression of severity
I (2)
ical impression of severity
I (3)
ical impression of severity
I (2)
ical impression of severity
I (3)
ical impression of severity
I (3)
ical impression of severity
I (3)
ical impression of severity
I (2)
ical impression of severity
I (3)
; CHD  coronary heart disease; CMR  cardiovascular magnetic resonance; Cr  creatinine; CTA 
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May 29, 2012:1995–2027 Appropriate Use Criteria for Diagnostic CatheterizationFigure 2. Suspected CAD: Prior Noninvasive Stress TestingIndications 22 to 27 not covered in figure. CAD  coronary artery disease; ECG  electrocardiography.Figure 3. Suspected CAD: Prior Noninvasive Cardiac CT (Calcium Score and CTA)
*Coronary calcium score only rated for asymptomatic patients as these patients are the population in which it is used. CT  computed tomography; CTA  computed tomog-
raphy angiography.
2018 Patel et al. JACC Vol. 59, No. 22, 2012
Appropriate Use Criteria for Diagnostic Catheterization May 29, 2012:1995–2027Figure 4. Patients With Known Obstructive CADCAD  coronary artery disease; PCI  percutaneous coronary intervention.Figure 5. Evaluation of ArrhythmiasIndication 63 for newly diagnosed LBBB is not represented in this figure and was rated as “uncertain.” CHD  coronary heart disease; LBBB  left bundle branch block;
LV  left ventricular; NI  noninvasive; VF  ventricular fibrillation; VT  ventricular tachycardia.
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May 29, 2012:1995–2027 Appropriate Use Criteria for Diagnostic CatheterizationFigure 6. Preoperative Coronary Evaluation: Patients With No Prior Noninvasive Stress TestingMETS  metabolic equivalents.Figure 7. Evaluation of Valvular Disease
Preoperative assessment before valvular surgery is not represented in this figure and is rated “appropriate.” *Indication 90 for acute moderate or severe mitral or aortic
regurgitation is not represented in this figure. Rating for concordant imaging is “uncertain” and conflicting imaging is “appropriate.” NI  noninvasive.
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Diagnostic cardiac catheterization incorporates both imaging
and hemodynamic procedures aimed at providing information
to document specific cardiovascular disease states as well as
help care for and improve the health of patients with known or
suspected heart disease. The AUC are meant to provide
guidance concerning the rational and timely use of diagnostic
cardiac catheterization and coronary angiography. The current
document provides an evaluation of many of the indications
commonly considered in clinical practice. The writing group
felt that review of the recommendations by general procedures
and indications would be of the highest utility to clinical practice.
10.1. Assessment for CAD
Several sets of indications were rated regarding the use of
invasive coronary angiography for the evaluation of CAD.
The writing group felt that the decision to include left heart
catheterization, left ventriculography, and perhaps other
invasive procedures with coronary angiography should be at
the discretion of the operator, depending on the clinical
situation, the presence or absence of noninvasive assess-
ments of LV function and pulmonary pressures, and the
perceived accuracy of these noninvasive results.
In general, these indications were grouped by the clinical
suspicion for acute coronary syndromes, suspected or known
obstructive CAD, use of adjunctive invasive diagnostic
technologies, evaluation of arrhythmias, and preoperative
evaluation. Although these scenarios represented many
common clinical indications for the evaluation of CAD, the
writing group acknowledges that this is not comprehensive
and thus there are likely clinical scenarios encountered in
practice that are not rated in this document. Nevertheless, review
of these scenarios should provide clinicians guidance on the use of
coronary angiography.
Overall, patients with definite or suspected acute coronary
syndromes were rated as appropriate for coronary angiography.
These ratings reflect the current management and risk strati-
fication of patients with acute coronary syndrome (ACS),
which usually involves defining the presence, location, and
degree of coronary stenosis and is based on abundant clinical
studies on the management of ACS patients that used coro-
nary angiography. Alternatively, in patients without known
CAD, referral directly for coronary angiography for the suspi-
cion of obstructive disease was felt to be appropriate only in
symptomatic patients with a high pretest probability. The
remaining patients (asymptomatic patients and symptomatic
patients with low or intermediate pretest probability) were felt
to be uncertain or inappropriate for a management strategy that
used coronary angiography as the initial diagnostic test.
In patients with prior noninvasive testing, coronary an-
giography was rated inappropriate for asymptomatic pa-
tients with low-risk findings. Symptomatic patients with
intermediate- or high-risk findings or equivocal/discordant
noninvasive findings were rated appropriate for coronaryangiography. Coronary calcium scores, regardless of sever-
ity, were rated as inappropriate indications for invasive
coronary angiography in asymptomatic patients. The tech-
nical panel was not asked to rate calcium scores in symp-
tomatic patients as this test is usually only performed in
asymptomatic patients to assess risk. For patients with
known CAD, asymptomatic patients following revascular-
ization and medically managed patients with stable symp-
toms and low-risk noninvasive test findings were rated
inappropriate in general for coronary angiography, whereas
patients with high-risk noninvasive findings or those with
limiting or worsening symptoms were rated as appropriate.
Several clinical scenarios related to the use of coronary
angiography in the evaluation of certain cardiac arrhythmias
were developed. Coronary angiography was rated as appro-
priate for patients resuscitated after cardiac arrest (assuming
return of reasonable neurologic function) and for those with
sustained VT regardless of symptoms. The other scenarios devel-
oped related to syncope, new onset atrial fibrillation/flutter, high-
degree atrioventricular block, or new LBBB and were generally
inappropriate for patients with a low coronary heart disease
(CHD) risk and uncertain with a high CHD risk.
Scenarios for patients scheduled for noncardiac surgical
procedures were also rated. In the preoperative setting for
noncardiac surgery, direct catheterization and angiography
was not generally considered appropriate unless the patient
had significant risk factors or was undergoing transplanta-
tion of a solid organ or vascular surgery.
10.2. Assessment for Conditions Other Than CAD
Assessment of intracardiac and pulmonary pressures and
other testing such as measurement of cardiac output were
evaluated primarily in the setting of valvular heart disease,
cardiomyopathies, and pulmonary hypertension. In the
section on CAD assessment, the scenarios developed consid-
ered the use of coronary angiography and considered other
procedures during the invasive evaluation (e.g., left heart
catheterization, left ventriculography) as secondary to the
primary purpose of the evaluation and at the discretion of the
operator. In a similar format, the scenarios developed in this
section rated the use of the hemodynamic evaluations and
considered coronary angiography as secondary to the primary
purpose of the evaluation and at the discretion of the operator.
It should be noted that, in general, for patients with
planned valvular surgery, preoperative catheterization for
coronary anatomy was rated as appropriate. Additionally, in
patients with symptomatic and severe valvular heart disease
with discordant clinical and noninvasive imaging findings,
hemodynamic assessment was rated as appropriate. Specific
groups such as those with low transvalvular gradient, depressed
LV function or decreased cardiac output were rated as appro-
priate for further evaluation using hemodynamic studies.
Patients without symptoms, with mild to moderate ste-
nosis or concordant clinical and noninvasive findings were
generally rated as inappropriate for diagnostic catheteriza-
tion procedures with hemodynamic assessment. Those
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uncertain. Asymptomatic patients with valvular heart disease
were rated based on the noninvasive findings alone since
discordance between a clinical impression and noninvasive
findings in these patients would not be easily determined.
Patients with pulmonary hypertension, either clinically sus-
pected or documented and requiring evaluation for pharmaco-
logical therapy, were identified as appropriate for invasive
hemodynamic assessment at rest as well as with provocative
maneuvers (exercise or pharmacological challenge).
Specific groups such as those suspected of pericardial
disease, intracardiac shunts, tamponade, suspected cardio-
myopathy or patients who have received cardiac transplant
were rated as appropriate for hemodynamic studies and
endomyocardial biopsy.
10.3. Application of the Criteria
In their work developing and rating these clinical scenarios, the
writing group and technical panel focused on the multiple goals
of diagnostic cardiac catheterization and coronary angiography
and common clinical scenarios seen in clinical practice. Clinical
scenarios and ultimately the ratings of the technical panel were
focused on obtaining information from the procedure that
should help in the management of patients with suspected or
known heart disease including providing needed reassurance
about the clinical status of the patient. Additionally, the
diagnostic catheterization AUC was written with recognition
that these indications would be linked with the coronary revascu-
larization AUC. In fact, the hope of the writing group was to
develop a system that would inform patients and clinicians to
increase the right patients undergoing appropriate invasive cathe-
terization procedures before discussions and considerations around
revascularization.
With these goals in mind, there are many potential appli-
cations for the AUC in this document. Decision support and
educational tools should be developed. Ideally, these would
translate these ratings into clinical tools used at the point of
care to aid clinicians and patients in the decision to perform or
undergo an invasive procedure. Figures 1 to 7 are meant to
rovide some initial algorithms for the overall ratings.
Facilities and payers may choose to use these criteria,
ither prospectively in the design of protocols or review
rocedures, or retrospectively for quality reports. It is hoped
hat payers would use these criteria to ensure that their
embers receive necessary, beneficial, and cost-effective
ardiovascular care, rather than for other purposes. It is
xpected that services performed for appropriate and/or
ncertain indications will receive reimbursement. In con-
rast, services performed for inappropriate indications may
equire additional documentation to justify payment because
f the unique circumstances or the clinical profile that may
xist in such a patient. This additional documentation
hould not be required for uncertain indications. It is critical to
mphasize that the writing group, technical panel, AUC Task
orce, and clinical community do not believe an uncertainating justifies denial of reimbursement for these invasive arocedures. Rather, uncertain ratings are those in which the
vailable data vary and many other factors exist that may affect
he decision to perform or not perform cardiac catheterization
nd coronary angiography. The opinions of the technical panel
ften varied for these indications, reflecting that additional
esearch is needed. Indications with high clinical volume that
re rated as uncertain identify important areas for further research.
he writing group and technical panel favor the collaborative
nteraction between patients, referring clinicians, and cardiologists
n determining the need for these invasive procedures.
When evaluating physician or facility performance, AUC
hould be used in conjunction with efforts that lead to quality
mprovement. Prospective preauthorization procedures, if put
n place, are most effective once a retrospective review has
dentified a pattern of potential inappropriate use. Because
hese criteria are based on current scientific evidence and the
eliberations of the technical panel, they should be used
rospectively to generate future discussions about reimburse-
ent, but should not be applied retrospectively to cases
ompleted before issuance of this report or documentation of
enters/providers performing an unexpectedly high proportion
f inappropriate cases as compared with their peers.
The writing group recognizes that these criteria will be
valuated during routine clinical care. To that end, specific data
elds such as symptom status, presence or absence of acute
oronary syndrome, history of CAD or revascularization, and
ype of noninvasive testing and findings will be required to
etermine individual appropriate use ratings. It is recognized
hat the characterization of symptoms is inherently subjective,
nd there is variability in the interpretation of many noninva-
ive tests. Fundamental to the application of the AUC is the
nderstanding that the characterization of symptoms or inter-
retation of noninvasive tests is performed in a manner such
hat independent qualified reviewers would reach the same
onclusions or support the conclusions of the individual physician
bout symptoms or noninvasive test results.
The primary objective of this report is to provide guid-
nce regarding the use of diagnostic catheterization includ-
ng coronary angiography, left heart catheterization and left
entriculography, and right heart catheterization for a diverse
et of clinical scenarios. As with previous AUC documents,
onsensus among the raters was desirable, but an attempt to
chieve complete agreement within this diverse panel would
ave been artificial and was not the goal of the process. Two
ounds of ratings with substantial discussion among the tech-
ical panel members between the ratings did lead to some
onsensus among panelists. However, further attempts to drive
onsensus would have diluted true differences in opinion
mong panelists and, therefore, was not undertaken.
Future research analyzing patient outcomes for indications
ated as appropriate and inappropriate will help ensure the equi-
able and efficient allocation of resources for cardiac catheteriza-
ion. Further exploration of the indications rated as “uncertain”
ill help generate the information required to further define theppropriate use of cardiac catheterization procedures. Addition-
2022 Patel et al. JACC Vol. 59, No. 22, 2012
Appropriate Use Criteria for Diagnostic Catheterization May 29, 2012:1995–2027ally, the criteria will need to be updated with the publication of
ongoing trials in imaging and revascularization occurs.
In conclusion, this document represents the current
understanding of the clinical utility of diagnostic cardiac
catheterization. It is intended to provide a practical guide to
clinicians and patients when these procedures.
Appendix A: Additional Diagnostic
Catheterization Definitions
TIMI Risk Score—For Patients With Suspected ACS (23):
Variables (1 point each)
• Age 65 years
• 3 risk factors (hypertension, diabetes mellitus, family
history, lipids, smoking)
• Known CAD (stenosis 50%)
• Aspirin use in past 7 days
• Severe angina (2 episodes within 24 hours)
• ST-segment deviation 0.5 mm
• Elevated cardiac markers
Risk of death or ischemic event through 14 days
• Low: 0 to 2 (8.3% event rate)
• Intermediate: 3 to 4 (19.3% event rate)
• High: 5 to 7 (41% event rate)
GRACE ACS Risk Model (24):
At admission (in-hospital/to 6 months)
• Age
• Heart rate
• Systolic blood pressure mm Hg
• Creatinine
• Congestive heart failure Killip class
• Cardiac arrest at admission
• ST-segment deviation
• Elevated cardiac enzymes/markers
At discharge (to 6 months)
• Age
• Heart rate
• Systolic blood pressure mm Hg
• Creatinine
• Congestive heart failure
• In-hospital PCI
• In-hospital CABG
• Past history of myocardial infarction
• ST-segment depression
• Elevated cardiac enzymes/markers
Appendix B: Additional Methods
Relationships With Industry and Other Entities
The American College of Cardiology Foundation and the
Society for Cardiovascular Angiography and Interventionsand its partnering organizations rigorously avoid any actual,
perceived, or potential conflicts of interest that might arise
as a result of an outside relationship or personal interest of
a member of the technical panel. Specifically, all panelists
were asked to provide disclosure statements of all relation-
ships that might be perceived as real or potential conflicts of
interest. These statements were reviewed by the Appropri-
ate Use Criteria Task Force, discussed with all members of
the technical panel at the face-to-face meeting, and updated
and reviewed as necessary. A table of disclosures by all
participants, listed in Appendix C, in the Appropriate Use
Criteria for Diagnostic Catheterization can be found in
Appendix D. In addition, to ensure complete transparency,
complete disclosure information—including relationships
not pertinent to this document—is available online as a
document supplement.
Literature Review
The technical panel members were asked to refer to the
relevant guidelines for a summary of the relevant literature,
guideline recommendation tables, and reference lists pro-
vided for each indication table when completing their
ratings (Online Appendix).
Appendix C: ACCF/SCAI/AATS/AHA/ASE/
ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS
2012 Appropriate Use Criteria For Diagnostic
Catheterization Participants
Diagnostic Catheterization Writing Group
Manesh R. Patel, MD, FACC—Co-Chair, Appropriate
Use Criteria for Diagnostic Catheterization Writing
Group—Assistant Professor of Medicine, Division of Car-
diology, Assistant Director, Cardiac Catheterization Lab,
Duke University Medical Center, Durham, NC
Steven R. Bailey, MD, FACC, FSCAI, FAHA—Co-
Chair, Appropriate Use Criteria for Diagnostic Catheter-
ization Writing Group—Chair, Division of Cardiology,
Professor of Medicine and Radiology, Janey Briscoe Dis-
tinguished Chair, University of Texas Health Sciences
Center, San Antonio, TX
Robert O. Bonow, MD, MACC, MACP, FAHA—
Goldberg Distinguished Professor, Director, Center for
Cardiovascular Innovation, Northwestern University Fein-
berg School of Medicine, Chicago, IL
Charles E. Chambers, MD, FACC, FSCAI—Professor
of Medicine and Radiology, Pennsylvania State University;
Director, Cardiac Catheterization Laboratories, Milton S.
Hershey Medical Center, Hershey, PA
Paul S. Chan, MD, MSc—Assistant Professor of Inter-
nal Medicine, Saint Luke’s Mid America Heart Institute,
Kansas City, MO
Gregory J. Dehmer, MD, FACC, FSCAI, FACP,
FAHA—Past President, Society for Cardiovascular An-
giography and Interventions, Professor of Medicine, Texas
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New York, NY
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